Phenotypes associated with this allele

• Allele Symbol: Cyba^tm1Dgh
• Allele Name: targeted mutation 1, David G Harrison
• Allele ID: MGI:5775909
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Cyba^tm1Dgh/Cyba^tm1Dgh	B6.Cg-Cyba^tm1Dgh	MGI:5779409

Genotype
MGI:5779409

cn1

• Allelic Composition: Cyba^tm1Dgh/Cyba^tm1Dgh
• Genetic Background: B6.Cg-Cyba^tm1Dgh

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal redox activity ( J:231269 )

♂ • markedly reduced superoxide production in the subfornical organ (SFO) after 14 days of angiotensin II infusion in mutant mice that receive SFO-targeted intracerebroventricular (ICV) injection of adenovirus expressing cre-recombinase (AdCre) relative to control mice, as detected by dihydroethidium fluorescence

cardiovascular system

abnormal systemic arterial blood pressure regulation ( J:231269 )

♂ • power spectral analysis of mean arterial pressure revealed that the power of low-frequency oscillations is not significantly increased after 14 days of angiotensin II infusion in AdCre-treated mice, unlike in control mice

decreased heart rate variability ( J:231269 )

♂ • power spectral analysis of heart rate variability revealed that angiotensin II treatment fails to increase the low-frequency/high-frequency ratio in AdCre-treated mice, unlike in control mice

decreased heart rate ( J:231269 )

♂ • reduced heart rate in AdCre-treated mice relative to control mice both before and during angiotensin II infusion

abnormal systemic arterial blood pressure ( J:231269 )

♂ • only transient increase in mean arterial pressure (MAP) at days 1-4 of angiotensin II infusion followed by a return to normal values at days 5-13 in AdCre-treated mice, unlike the progressive increase in MAP induced by angiotensin II treatment in control mice

decreased mean systemic arterial blood pressure ( J:231269 )

♂ • blunted hypertensive response at 14 days of angiotensin II infusion in AdCre-treated mice relative to control mice (MAP = 97 +/- 15 versus 154 +/- 6 mm Hg, respectively)

nervous system

abnormal nervous system physiology ( J:231269 )

♂ • markedly reduced superoxide production in the SFO after 14 days of angiotensin II infusion in AdCre-treated mice relative to control mice

abnormal sympathetic nervous system physiology ( J:231269 )

♂ • markedly attenuated sympathetic outflow after angiotensin II infusion in AdCre-treated mice relative to control mice

immune system

abnormal T cell activation ( J:231269 )

♂ • reduced accumulation of activated CD69+ and CD44^high T-cells in aortic tissue after angiotensin II treatment in AdCre-treated mice relative to control mice

decreased inflammatory response ( J:231269 )

♂ • failure to show increased vascular inflammation after angiotensin II treatment in AdCre-treated mice relative to control mice, as shown by reduced accumulation of CD45+ and CD3+ cells and activated CD69+ and CD44^high T-cells in aortic tissue

hematopoietic system

abnormal T cell activation ( J:231269 )

♂ • reduced accumulation of activated CD69+ and CD44^high T-cells in aortic tissue after angiotensin II treatment in AdCre-treated mice relative to control mice